AstraZeneca reviews potential Bristol Myers deal, Barclays comments
Go back to AstraZeneca reviews potential Bristol Myers deal, Barclays comments| ASTRAZENECA PLC (NASDAQ: AZN) | Delayed: 92.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.77 | 52 Week High | $35.04 | |||
| Open | $92.77 | 52 Week Low | $26.97 | |||
| Day High | $92.77 | P/E | N/A | |||
| Day Low | $92.77 | EPS | $0.00 | |||
| Volume | 3,071,758 | |||||
| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 66.82 -1.27 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.09 | 52 Week High | $77.12 | |||
| Open | $67.24 | 52 Week Low | $49.03 | |||
| Day High | $67.72 | P/E | 43.39 | |||
| Day Low | $66.58 | EPS | $1.54 | |||
| Volume | 4,825,368 | |||||
